11:02 AM EDT, 05/18/2017 (MT Newswires) --
Gainers in Continental Europe were led by Criteo (CRTO), a French technology company, 3.3% higher, followed by Nabriva Therapeutics (NBRV), an Austria-based clinical-stage biopharmaceutical company, up by 3.1% and Cellectis (CLLS), a French genome engineering company, 1.7% higher. TiGenix (TIG), a Belgium-based biopharmaceutical company, was up by 1.5%.
In the UK, Shire (SHPG), a biopharmaceutical company, was 4.7% higher, followed by Royal Bank of Scotland (RBS), up by 3% and Trinity Biotech (TRIB), a manufacturer of medical diagnostic products, up by 2.8%. Barclays Bank (BCS) was 2.3% higher.
Decliners in Continental Europe were led by Telecom Italia (TI), down by 3.5%, followed by CGG (CGG), a manufacturer of geophysical equipment, 3.1% lower and Banco Santander (SAN) and AB InBev (BUD), a Belgium-based company engaged in the brewers industry, both 2.7% lower.
And, in the UK, Adaptimmune Therapeutics (ADAP), a clinical-stage biopharmaceutical company, was down by 2.9%, followed by Randgold Resources (GOLD), a gold-mining company, 2.4% lower and Fly Leasing (FLY), an aircraft leasing company, down by 1.3%. Akari Therapeutics (AKTX), a development-stage biopharmaceutical company, was 1.2% lower.
Price: 49.90, Change: +0.96, Percent Change: +1.96
Copyright © 2017 MTNewswires. All rights reserved. MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.